JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 16 No. 11 986-989
© 1975 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tofe, A. J.
Right arrow Articles by Harvey, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tofe, A. J.
Right arrow Articles by Harvey, W. J.

Correlation of Neoplasms with Incidence and Localization of Skeletal Metastases: An Analysis of 1,355 Diphosphonate Bone Scans

Andrew J. Tofe, Marion D. Francis and William J. Harvey

The Procter & Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio

Correspondence: For reprints contact: A. J. Tofe, Miami Valley Laboratories, The Procter & Gamble Co., P.O. Box 39175, Cincinnati, Ohio 45247.

ABSTRACT

A total of 1,355 patients from clinical trials with the 99mTc-labeled bone agent, Osteoscan® (99mTc-Sn·EHDP), has shown a higher incidence of skeletal abnormalities than previously reported. Overall in this study, 60% of bone scans were abnormal in patients with nonosseous neoplasms. Carcinoma of breast, lung, and prostate yielded 67%, 64%, and 62% skeletal involvement, respectively. Over 50% of all the skeletal abnormalities for the neoplastic indications were detected in the thorax and vertebra while the skull, pelvis, and extremities accounted for 22%, 38%, and 34%, respectively.




This article has been cited by other articles:


Home page
 Am. J. Neuroradiol.Home page
A.J. Nemeth, J.W. Henson, M.E. Mullins, R.G. Gonzalez, and P.W. Schaefer
Improved Detection of Skull Metastasis with Diffusion-Weighted MR Imaging
AJNR Am. J. Neuroradiol., June 1, 2007; 28(6): 1088 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Hamaoka, J. E. Madewell, D. A. Podoloff, G. N. Hortobagyi, and N. T. Ueno
Bone Imaging in Metastatic Breast Cancer
J. Clin. Oncol., July 15, 2004; 22(14): 2942 - 2953.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. M. Dougherty, E. A. G. Blomme, A. J. Koh, J. E. Henderson, K. J. Pienta, T. J. Rosol, and L. K. McCauley
Parathyroid Hormone-related Protein as a Growth Regulator of Prostate Carcinoma
Cancer Res., December 1, 1999; 59(23): 6015 - 6022.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
R. AFRA, D. L. BOARDMAN, J. M. KABO, and J. J. ECKARDT
Avulsion Fracture of the Lesser Trochanter as a Result of a Primary Malignant Tumor of Bone. A Report of Four Cases
J. Bone Joint Surg. Am., September 1, 1999; 81(9): 1299 - 304.
[Full Text]

Home page
 Clin. Chem.Home page
P. Magnusson, L. Larsson, G. Englund, B. Larsson, P. Strang, and L. Selin-Sjogren
Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain
Clin. Chem., August 1, 1998; 44(8): 1621 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
A. D. AARON
Current Concepts Review - Treatment of Metastatic Adenocarcinoma of the Pelvis and the Extremities
J. Bone Joint Surg. Am., June 1, 1997; 79(6): 917 - 32.
[Full Text]

Home page
 Palliat MedHome page
V. Ventafridda, A. Sbanotto, and F. De Conno
Review article : Pain in prostatic cancer
Palliative Medicine, July 1, 1990; 4(3): 173 - 184.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1975 by the Society of Nuclear Medicine.